FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications

The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Related Keywords

,Robert Harrington ,Arthurl Bloomfield ,Janssen Research Development ,Department Of Medicine At Stanford University ,Bristol Myers Squibb ,Janssen Pharmaceutical ,Stanford University ,Janssen Research ,